Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial.

Mafalda OliveiraHope S RugoSacha J HowellFlorence DalencJavier CortesHenry L GomezXichun HuMasakazu ToiKomal JhaveriPetr KrivorotkoSibylle LoiblSerafin Morales MurilloMeena OkeraZbigniew NoweckiYeon Hee ParkJoo Hyuk SohnEriko TokunagaSamih YousefLyudmila ZhukovaMarta FulfordHaylee AndrewsIan WadsworthCelina D'CruzNicholas C Turnernull null

Published in: The Lancet. Oncology (2024)

AstraZeneca.

Keyphrases

double blind
patient reported
placebo controlled
clinical trial
phase iii
study protocol
phase ii
metastatic breast cancer
randomized controlled trial
open label
breast cancer risk
childhood cancer